Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide versus placebo for refractory inflammatory bowel disease in children and young adults
2005-005414-20Phase 3Active
- Sponsor
- IRCCS Burlo Garofolo
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis comparing Thalidomide with Placebo (2 arms). Primary endpoints: Clinical remission in Crohn's disease, Clinical remission in ulcerative colitis and 4 more. Started Jan 2006; status: active.
02
Drugs
thalidomide
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2005-005414-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005414-20.